Abstract: The invention relates to DNA sequences coding for PTH variants, to PTH variants, expression vectors, bacterial hosts, uses and therapeutic compositions.

Abstract: pPTH, bPTH or hPTH is modified by deletions from the natural C- and/or N-terminus. The modified compounds are useful active ingredients in therapeutic compositions. The therapeutic compositions do not stimulate renal adenylate cyclase but, rather, effect chondrocyte proliferation, that is to say, they exhibit a mitogenic and bone-specific effect.

Abstract: The invention relates to DNA sequences coding for PTH variants, to PTH variants, expression vectors, bacterial hosts, uses and therapeutic compositions.

Abstract: The invention relates to a method of preparing N.sup.6 -substituted NAD, NADP or FAD by Dimroth rearrangement, wherein the rearrangement is carried out without preceding reduction and subsequent reoxidation.

Abstract: The invention relates to a method for isolating a polysaccharide extracellularly producing bacteria from a mixed culture of non-polysaccharide and polysaccharide producing bacteria, The method uses a streaking technique on a nutrient medium containing unsubstituted gellan as a gellant. The polysaccharide extracellularly producing bacteria are isolated by the act of non-polysaccharide extracellularly producing bacteria sinking into the nutrient medium. However, the polysaccharide extracellularly producing bacteria do not sink into the nutrient medium. The isolated cells are capable of producing an exopolysaccharide such as P4. Further the isolated cells are capable of producing gellan. The specific polysaccharide producing bacteria are of the genera Auromonas, Pseudomonas and Sphingomonas.

Abstract: Novel non-elastomeric biomedical adhesive compositions for calcified tissues, are described. The compositions are characterized by a network structure which is obtained by the reaction of a polyisocyanate having at least two isocyanate groups with at least one polyol which possesses surface wetting properties with the participation of compounds selected from calcium and phosphorus, optional in the presence of a catalyst. The polyisocyanate is selected from aliphatic, alicyclic and aromatic compounds and preferred amounts are in the range of 20% to 80% by weight of the total amount of reactants. The polyol is selected from polyalkylene ether glycols and polyester glycols containing between 25 to 75 carbon atoms and preferred amounts are in the range of 10% to 80% by weight of the total amount of reactants. The adhesive compositions were found to produce a fast bonding of the calcified tissues, with a joint strength of above 0.5 N/sq.mm.

Abstract: Invertase is produced by a process wherein, first the yeast cells are disrupted to produce a disrupted cell suspension, second the disrupted cell suspension is adjusted to an acidic pH, third denatured undersired proteins are removed with the cell detritus and lastly the invertase is isolated. The improvement of the invention to the state of the art is that it comprises subjecting the disrupted cell suspension prior to removing the undesired proteins and cell detritus, to a pH of less than 4.5 and to a heat treatment in a continuous thermal denaturation system at a temperature in a range of from 44.degree. C. to about 51.degree. C.

Abstract: A sensor arrangement for flow injection analysis, includes an enzyme reactor and a chemical/physical sensor. The sensor arrangement is designed as a sealed module and a flow channel of great length is accommodated in the module. By this sensor arrangement, gases generated or consumed in the enzyme reactor are detected without interfering gas exchange with the environment.

Abstract: The invention relates to an enzyme electrode having a bienzyme system containing fungal peroxidase or horseradish peroxidase and one or more oxidases, and to the use of the electrode.

Abstract: The invention relates to a therapeutic composition (especially for bone lesions with cavity formation and parodontitis) containing a growth-stimulating material and a solid carrier, to such a material and to a process for the preparation thereof.

Abstract: The invention relates to a process for mild esterification of a sensitive carboxylic acid, in particular a suitably protected amino acid, with an alcohol component, the esterification according to the invention being carried out in the presence of 2,4,6-mesitylene-1-sulfonyl-3-nitro-1,2,4-triazolide (MSNT) and a weak base in an aprotic and non-basic solvent.

Abstract: The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration;R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydroxy and salts thereof, especially pharmaceutically acceptable salts.The compounds of formula I are prepared by fermentation using the strain So ce 12 (NCIB 12134) of the species Sorangium cellulosum and are effective antibiotics.

Abstract: Compounds of the formula I ##STR1## in which either R is methyl and there is a double bond in the 9,10-position, or in which R is hydrogen and there is a single bond in the 9,10-position, are highly active against Acarina which damage plants.

Abstract: The invention relates to a device for flow-injection analysis having a reaction loop, one or more pumps, an injection valve, one or more detectors and an evaluating device.

Abstract: The invention relates to a method for resolving carbamate racemates of amino acids or norephedrine by enzmatic resolution.

Abstract: The invention relates to an apparatus and a process for the bubble-free gassing of liquids, especially of culture media for propagating tissue cultures by means of a porous membrane filament system, whereby liquid media and gas are introduced into the culture. The porous membrane filaments include both hydrophobic and hydrophobic filaments.

Abstract: The invention relates to novel polycyclic alkaloids of formula ##STR1## in which R.sup.1 represents hydrogen or hydroxy, R.sup.2 represents hydrogen or acyl and A and B, independently of one another, each represents C.dbd.O or C--OH, and wherein the dashed line represents a C.dbd.C double bond at the position of the middle bond when A or B represents C.dbd.O, or at the position of the two outer bonds when A or B represents C--OH, a process for the manufacture of these compounds by fermentation of a novel microorganism of the species Myxococcus xanthus, the novel microorganism itself, pharmacetical preparations that contain the novel compounds, and the use of the novel compounds as antibiotics and as tumour-inhibiting agents and for the manufacture of pharmaceutical preparations.

Abstract: A process for the purfication of synthetic oligonucleotides is described which drastically simplifies the hitherto very time consuming purification process. The deprotection solution is adsorbed without being concentrated on a carrier having reversed phase properties and optionally ion exchanger properties, the oligonuleotides without lipophilic protecting group are removed, their protecting group is cleaved off from the adsorbed oligonucleotides, the adsorbed oligonucleotides are washed and eluted from the carrier and then purified in a manner known per se.

Abstract: Novel macrocyclic compounds of the formual I ##STR1## where the dotted line in the 9,10-position is a saturated bond or a double bond, alternatively, and R is hydrogen, methyl or certain acyl radicals, and R.sub.o is hydrogen, halogen, azido, thiol, hydroxyl or --OY, where Y is, among other radicals, an ether radical, a silyl group, a sulfonyl group, a sugar radical or a (thiol)acyl radical, and R being methyl if there is a double bond in the 9,10-position, have microbicidal properties for the control of phytopathogenic microorganisms. They can be employed in the customary formulation for the control of plant disease.

Abstract: The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration; R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydroxy or .beta.-glucopyranosyloxy, and to the hydrates and salts thereof, especially pharmaceutically acceptable salts.The compounds of formula I are prepared by fermentation using the strain So ce 12 (NCIB 12134) of the species Sorangium celulosum and are effective antiobiotics.